CN1198621C - Adhesive preparation containing estradiol - Google Patents
Adhesive preparation containing estradiol Download PDFInfo
- Publication number
- CN1198621C CN1198621C CNB018190901A CN01819090A CN1198621C CN 1198621 C CN1198621 C CN 1198621C CN B018190901 A CNB018190901 A CN B018190901A CN 01819090 A CN01819090 A CN 01819090A CN 1198621 C CN1198621 C CN 1198621C
- Authority
- CN
- China
- Prior art keywords
- estradiol
- patch
- absorption enhancer
- adhesive phase
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Abstract
An adhesive preparation which comprises a flexible support and formed on one side thereof a pressure-sensitive adhesive layer comprising a drug, an absorption accelerator, and a pressure-sensitive adhesive, wherein (i) the drug is estradiol, (ii) the absorption accelerator comprises a combination of at least either of sorbitan monolaurate and polyethylene glycol monolaurate and at least one member selected among higher fatty acid esters which are liquid at room temperature and hydrocarbons which are liquid at room temperature, and (iii) the pressure-sensitive adhesive is an acrylic one.
Description
Technical field
The present invention relates to contain the patch of estradiol.
Background technology
As among the women after amenorrhea observed climacteric obstacle, osteoporosis, A Erchamo dementia etc. reason, point out it is because be accompanied by the minimizing of the estrone of amenorrhea.At present, for above-mentioned symptom, carry out the replacement therapy of oral formulations.
But, under the situation of oral formulations, because metabolism rapidly in digestive tract and liver needs a large amount of administrations.In recent years, as the method for avoiding metabolism in liver (first pass effect), developing by skin surface the medicine band agent of the percutaneous absorption of administration in vivo always.
In general, since low through skin medicine transmitance, so proposed the endermic absorbefacient method of raising medicine (for example, the spy opens flat 1-233213 communique, and the spy opens flat 5-178763 communique and the flat 6-205839 communique of Te Kai).
In addition, about estradiol, for example show also to have proposed to be used to improve in flat 3-502925 communique and the flat 6-503576 communique of Te Biao the absorption enhancer of estradiol skin absorption the spy as estrone.
But in these technology, though can improve the skin permeability of medicine, effect is insufficient, and the skin permeability improves and can not continue, and has again, aspect safety and economy, can't satisfy.
The object of the present invention is to provide the skin permeability of estradiol good, long-time continuously lasting skin permeability that improves and good patch aspect safety and economy.
Present inventors have carried out research with keen determination for reaching this purpose, found that, in the patch that is provided with the adhesive phase that contains estradiol and absorption enhancer and binding agent, by using specific absorption enhancer, reach the purpose of the invention described above, thereby finished the present invention.
Disclosure of the Invention
That is, the invention provides a kind of patch, on the single face of softish support, be provided with in the patch of the adhesive phase that contains medicine and absorption enhancer and binding agent,
(I) this medicine is an estradiol,
(ii) this absorption enhancer by be selected from Span-20 and polyethylene glycol monolaurate more than one and to be selected from room temperature be that more than one of aqueous high-grade aliphatic ester and hydro carbons are formed,
(iii) this binding agent is an acrylic adhesive.
The best mode that carries out an invention
In the present invention the absorption enhancer of Shi Yonging be selected from Span-20 and polyethylene glycol monolaurate more than one and to be selected from room temperature be that more than one mixture of aqueous high-grade aliphatic ester and hydro carbons is important.When only using this mixture, can obtain the lasting for a long time patch of skin permeability of good Percutaneously absorbable and estradiol.
This absorption enhancer only is when being selected from more than one of Span-20 and polyethylene glycol monolaurate, the patch that can not obtain having above-mentioned characteristic.Equally, only be to be selected from when at room temperature being more than one of aqueous high-grade aliphatic ester and hydro carbons, can not obtain this patch.
In the present invention, be selected from room temperature be aqueous high-grade aliphatic ester and hydro carbons more than one, the mixture of high-grade aliphatic ester and hydro carbons preferably.Why, be because not only the absorbability of estradiol improve and persistence aspect, and, all be effective aspect the adhesion of skin, economy.
When adopting the mixture of above-mentioned high-grade aliphatic ester and hydro carbons, preferred 0.1: 0.9 to 0.8: 0.2 of its mixing ratio.
And, absorption enhancer among the present invention from the absorbability that the absorbability of estradiol improves, continues improve, adhesion to skin, economy or to the resistance to water aspect of balneation etc., the mixture of preferred especially Span-20, high-grade aliphatic ester and hydro carbons.
As of the present invention at room temperature be aqueous high-grade aliphatic ester, can enumerate isopropyl myristate, isopropyl palmitate, Palmic acid isostearate, ethyl oleate, Cetiol, decyl oleate, ethyl sebacate and lauric acid hexyl ester etc.Wherein, from the absorbefacient raising of estradiol, the persistence and the skin irritation aspect of continuously long effect, preferred isopropyl myristate, isopropyl palmitate or ethyl oleate.Further, as particularly preferred, can enumerate isopropyl myristate.
As hydro carbons of the present invention, can enumerate liquid paraffin, squalane, Squalene, Ultralube W 389 and vaseline etc.Wherein, from the absorbefacient raising of estradiol, lasting absorbefacient raising, economy and adhesion aspect, preferred liquid paraffin and/or squalane.
In the present invention, more than one the content that is selected from Span-20 and polyethylene glycol monolaurate in the adhesive phase is preferably more than the 2wt%, below the 10wt%.Content is lower than 2wt%, is difficult to improve the sufficient skin permeability of medicine, if surpass 10wt%, because the raising effect of the skin permeability of medicine reaches capacity, from safety and economy aspect, is not preferred then.
In addition, being selected under the room temperature is that more than one content in adhesive phase of aqueous high-grade aliphatic ester and hydro carbons are preferably more than the 5wt%, below the 35wt%.Content is lower than 5wt%, is difficult to continue the skin permeability and the continuously long skin permeability of sufficient medicine.In addition, if surpass 35wt%,,, be not preferred then from the economy aspect because the raising effect of the skin permeability of medicine reaches capacity.In addition, patch is applied to after the skin, when it is peelled off, is easy to residual glue on skin.
As acrylic adhesive of the present invention, preferably (methyl) alkyl acrylate with carbon number 2～20 is main constituent, contains following (methyl) acrylic acid (methyl) alkyl acrylate copolymer of 10wt%.As (methyl) alkyl acrylate of this carbon number 2～20, can enumerate (methyl) ethyl acrylate, (methyl) butyl acrylate, (methyl) acrylic acid pentyl ester, (methyl) Hexyl 2-propenoate, (methyl) acrylic acid heptyl ester, (methyl) 1-Octyl acrylate, (methyl) 2-EHA, (methyl) acrylic acid ester in the ninth of the ten Heavenly Stems, (methyl) acrylic acid cetyl ester and (methyl) dodecylacrylate etc.Wherein, from adhesion, preferred especially is the copolymer of main constituent with the 2-EHA.
In the present invention, for example above-mentioned " (methyl) alkyl acrylate " is meant alkyl acrylate or alkyl methacrylate.
In addition, adjusting under the purpose of adhesion, can be in acrylic adhesive be binding agent, siloxane-based binding agent with the amount mixing vinegar vinyl acetate that is lower than acrylic adhesive.
The so-called estradiol of the present invention is meant natural type estrone and eticyclin and derivant thereof, can enumerate for example estradiol, estradiol benzoate, dipropionate estradiol, estradiol valerate and ethinyl estradiol etc.Wherein preferred estradiol.
More than the preferred 0.4wt% of the content of estradiol of the present invention in patch, below the 2.5wt%, more than the preferred especially 0.6wt%, more than the 2.0wt%.Content is lower than 0.4wt%, is difficult to obtain the skin permeability of the medicine of q.s.In addition, if content surpasses 2.5wt%, then owing to the remaining medication amount of using the back patch increases, so be uneconomic.
As making medicine be contained in method in this adhesive phase, can adopt known method in the past.For example, originally drug solution is mixed in the solution shape binding agent, make the method for the adhesive phase that contains medicine then, perhaps, in not containing medicine or insufficient adhesive phase that contains medicine, by dipping, roll attached or spraying etc., make it to contain the method for the medicine that the percutaneous of q.s absorbs etc.
In addition, under the purpose of the cohesive force that improves adhesive phase, in adhesive phase of the present invention, also can carry out crosslinked.As this crosslinked method, can adopt the crosslinked of ultraviolet, γ line etc., perhaps carry out crosslinked method etc. by adding the cross-linking agent such as macromolecule that can form silicic acid anhydride, polyisocyanate compounds, organic metal salt, metal chelate compound, polyion complex.
And, in binding agent of the present invention, as required, also can add known in the past stabilizing agent, antioxidant, spice, antiseptic and pH regulator agent etc.Specifically, can enumerate for example stabilizing agents such as magnesium stearate, zinc stearate, Citric anhydride; Antioxidants such as ascorbic acid, tocopheryl acetate, vitamin E; Menthol, Camphora, Oleum menthae, Fructus Citri Limoniae wet goods spice; Antiseptic such as dibenzylatiooluene, p-Hydroxybenzoic acid isobutyl ester; PH regulator agent such as sodium citrate, monobasic sodium citrate, dibastic sodium phosphate, sodium dihydrogen phosphate etc.These can use separately, also can mix use more than a kind or 2 kinds.
As the support that uses in the present invention, as long as can be bonding with adhesive phase, the retentivity with self-shape be just passable, and there is no particular limitation to its material, shape etc.Can be selected from for example polymeric films such as polyester, polyolefin, polrvinyl chloride, polyurethanes and cellulose esters; By fibrous fabric, fabric, non-woven fabrics and paper such as polyester, polyolefin, polyurethanes, cellulose esters and polyamide; The porous membrane of forming by polyester, polyolefin, cellulose esters, polyurethanes and polyamide etc. and by these duplexers that are combined to form more than 2 kinds etc.There is no particular limitation for the thickness of this support, but from the property handled aspect, preferred 50～1000 μ m.
There is no particular limitation for the thickness of adhesive phase of the present invention, preferred 10～300 μ m, preferred especially 40～200 μ m.
As mentioned above, in the patch that is provided with the adhesive phase of forming by estradiol and acrylic adhesive and absorption enhancer, as absorption enhancer, be selected from more than one of Span-20 and polyethylene glycol monolaurate by use, with being selected from room temperature is more than one mixture of aqueous high-grade aliphatic ester and hydro carbons, and the skin permeability that can obtain estradiol is good, can continue the skin permeability continuously for a long time and also good patch aspect safety, economy.
Embodiment
Below by embodiment the present invention is described.In addition, among the embodiment, part and % refer to weight portion and weight % respectively.Have again,, the sticking card of patch to nude mouse, behind the sticking card, was taken a blood sample after 7 hours, 24 hours, adopt the estradiol in the radioimmunoassay quantitative blood for the blood Chinese medicine concentration among the embodiment.
Embodiment 1
As acrylic adhesive, in 24.3 parts of AE solution of forming by 90% 2-EHA, 7% methyl methacrylate, 3% acrylic acid (solid content 15%), add 5% acetone soln, 0.25 part of Span-20,1.0 parts of isopropyl myristates of 1.2 parts of estradiol, 0.05 part of polyvinylpyrrolidone, 19 parts of ethyl acetates, 13 parts of ethanol as cross-linking agent.Then it is applied on the divergence type film of silicone coating, so that the thickness of dried adhesive phase reaches 70 μ m, 60 ℃ of dryings 30 minutes, the PET film of bonding 12 μ m on the single face of adhesive phase obtained patch then.With gained patch stamping-out is φ (diameter) 27mm, and its sticking card is arrived the back of the about 140g of body weight except the nude mouse of hair.Behind the sticking card, take a blood sample after 7 hours, 24 hours, adopt the drug level in the radioimmunoassay quantitative blood.The results are shown in the table 1.As shown in table 1, the gained patch demonstrates high drug absorption.
Embodiment 2～8, comparative example 1～2
Except changing to the mixing composition shown in the table 1, the same with embodiment 1, obtain patch.
As shown in table 1, the patch of embodiment 2～8 demonstrates high drug absorption continuously for a long time.In contrast, shown in comparative example 1～2, as the sorbitan laurate of absorption enhancer or the patch of isopropyl myristate, the Percutaneously absorbable of medicine is insufficient for independent use.
Table 1
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 | Embodiment 7 | Embodiment 8 | Comparative example 1 | Comparative example 2 | |
| Estradiol acrylic adhesive Span-20 Vinlub 73 isopropyl myristate ethyl oleate saualane atoleine crosslinking agent | 1.2 | 1.2 | 0.8 | 1.2 | 1.2 | 1.8 | 1.2 | 1.2 | 1.2 | 1.2 |
| 72.8 | 85.3 | 74.1 | 73.7 | 73.7 | 82.7 | 72.8 | 78.3 | 72.8 | 92.8 | |
| 5 | 2.5 | 5 | 5 | 5 | - | 5 | - | - | 5 | |
| - | - | - | - | - | 5 | - | 5 | - | - | |
| 20 | 10 | 5 | 5 | - | - | 10 | 5 | 25 | - | |
| - | - | - | - | - | - | 10 | - | - | - | |
| - | - | 15 | - | 20 | 10 | - | 10 | - | - | |
| - | - | - | 15 | - | - | - | - | - | - | |
| 1 | 1 | 0.1 | 0.1 | 0.1 | 0.5 | 1 | 0.5 | 1 | 1 | |
| Blood Chinese medicine concentration: paste after 7 hours (pg/ml): paste after 24 hours | 4168 | 3802 | 3959 | 4103 | 3756 | 6432 | 3929 | 4005 | 2183 | 1343 |
| 1938 | 1462 | 2505 | 2342 | 1625 | 2362 | 1618 | 2156 | 960 | 812 |
Claims (2)
1. a patch is provided with on the single face of softish support in the patch of the adhesive phase that contains estradiol and absorption enhancer and binding agent,
(i) concentration of the estradiol in this patch is more than the 0.4wt%, below the 2.5wt%,
(ii) this absorption enhancer is by being selected from more than one of Span-20 and polyethylene glycol monolaurate, with be selected from isopropyl myristate, more than one compositions of liquid paraffin and squalane, more than one the concentration of absorption enhancer in adhesive phase that wherein is selected from Span-20 and polyethylene glycol monolaurate is more than the 2wt%, below the 10wt%, be selected from isopropyl myristate, the concentration of the absorption enhancer of more than one of liquid paraffin and squalane in adhesive phase is more than the 5wt%, below the 35wt%
(iii) this binding agent is an acrylic adhesive.
2. the described patch of claim 1, wherein this absorption enhancer is Span-20 and isopropyl myristate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP350657/2000 | 2000-11-17 | ||
| JP2000350657 | 2000-11-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1474695A CN1474695A (en) | 2004-02-11 |
| CN1198621C true CN1198621C (en) | 2005-04-27 |
Family
ID=18823846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB018190901A Expired - Fee Related CN1198621C (en) | 2000-11-17 | 2001-11-13 | Adhesive preparation containing estradiol |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP3935839B2 (en) |
| KR (1) | KR100533493B1 (en) |
| CN (1) | CN1198621C (en) |
| AU (1) | AU2002212763A1 (en) |
| WO (1) | WO2002040031A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1581156A4 (en) * | 2003-01-03 | 2007-03-07 | Dpc Products Inc | Gilsonite derived pharmaceutical delivery compositions and methods |
| JP7112256B2 (en) * | 2018-06-08 | 2022-08-03 | 株式会社日本触媒 | Adhesive composition and its use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2507068B2 (en) * | 1989-07-10 | 1996-06-12 | 積水化学工業株式会社 | Transdermal formulation |
| JPH0344326A (en) * | 1989-07-10 | 1991-02-26 | Sekisui Chem Co Ltd | Percutaneous absorption preparation |
| JP2718433B2 (en) * | 1989-09-08 | 1998-02-25 | シグナス インコーポレイテッド | Solid matrix system for transdermal drug delivery |
| JPH0827003A (en) * | 1994-07-22 | 1996-01-30 | Sekisui Chem Co Ltd | Percutaneously absorbable pharmaceutical preparation |
| JP4346696B2 (en) * | 1996-05-28 | 2009-10-21 | 久光製薬株式会社 | Transdermal therapeutic device |
| DE19918106A1 (en) * | 1999-04-22 | 2000-10-26 | Lohmann Therapie Syst Lts | Transdermal patches containing basic or neutral drug include adhesive (meth)acrylic acid polymer in alkali(ne earth) metal salt form |
-
2001
- 2001-11-13 AU AU2002212763A patent/AU2002212763A1/en not_active Abandoned
- 2001-11-13 CN CNB018190901A patent/CN1198621C/en not_active Expired - Fee Related
- 2001-11-13 KR KR10-2003-7006318A patent/KR100533493B1/en not_active IP Right Cessation
- 2001-11-13 WO PCT/JP2001/009915 patent/WO2002040031A1/en active IP Right Grant
- 2001-11-13 JP JP2002542404A patent/JP3935839B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP3935839B2 (en) | 2007-06-27 |
| KR100533493B1 (en) | 2005-12-06 |
| CN1474695A (en) | 2004-02-11 |
| KR20040011430A (en) | 2004-02-05 |
| WO2002040031A1 (en) | 2002-05-23 |
| JPWO2002040031A1 (en) | 2004-03-18 |
| AU2002212763A1 (en) | 2002-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0186019B1 (en) | Medicated dressing | |
| KR100693824B1 (en) | Transdermal therapeutic system with neutralized acrylic adhesive patch | |
| CA2033113C (en) | Estrogen-containing gel preparation | |
| KR970007900B1 (en) | Percutaneous pharmaceutical preparation | |
| KR100561255B1 (en) | Transdermal hormone-delivering therapeutic system | |
| JPH07258060A (en) | Skin whitening patch | |
| DE4241874A1 (en) | Medical patch for percutaneous administration | |
| AU782249B2 (en) | Patches containing buprenorphine hydrochloride | |
| AU2012332254A1 (en) | Dermal delivery compositions and methods | |
| WO2004100959A1 (en) | External patch containing estrogen and/or progestogen | |
| KR0163597B1 (en) | A percutaneous-administration type pharmaceutical preparation of nitroglycerin | |
| EP1385490B1 (en) | Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins | |
| EP0773028A1 (en) | Percutaneously absorbable preparation | |
| CN1198621C (en) | Adhesive preparation containing estradiol | |
| CN112826809B (en) | Stable tulobuterol percutaneous absorption preparation | |
| JP3523275B2 (en) | Patch | |
| MXPA02001152A (en) | Transdermal delivery of lasofoxifene. | |
| CN1187042C (en) | Plaster which contains steroids, and method for the production and use thereof | |
| WO2001049273A2 (en) | Pharmaceutical composition for transdermally administering hormones with an additive that enhances permeation | |
| EP2371360B1 (en) | Selegiline-containing adhesive preparation | |
| JP3792305B2 (en) | Medical adhesive composition | |
| AU2011324394B2 (en) | Felbinac-containing external patch | |
| DE19828274C2 (en) | Transdermal therapeutic system containing hormones and crystallization inhibitors | |
| JPH10316825A (en) | Adhesive composition | |
| JP2839635B2 (en) | Estradiol-containing patch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050427 Termination date: 20131113 |